BG106577A - Фибринолитично активен полипептид - Google Patents

Фибринолитично активен полипептид Download PDF

Info

Publication number: BG106577A
Authority: BG; Bulgaria
Prior art keywords: nat; polypeptide; transformed; seq; sequence
Prior art date: 1999-10-01

Application number

BG106577A

Other languages

Bulgarian (bg)

English (en)

Inventor

Thomas Boone

Huimin Li

Michael Mann

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-01

Filing date

2002-04-04

Publication date

2003-04-30

2002-04-04 Application filed by Amgen Inc. filed Critical Amgen Inc.

2003-04-30 Publication of BG106577A publication Critical patent/BG106577A/bg

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 51
229920001184 polypeptide Polymers 0.000 title claims abstract description 49
238000000034 method Methods 0.000 claims abstract description 42
208000007536 Thrombosis Diseases 0.000 claims abstract description 12
108010006035 Metalloproteases Proteins 0.000 claims abstract description 11
102000005741 Metalloproteases Human genes 0.000 claims abstract description 11
238000003259 recombinant expression Methods 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 72
108010090109 Fibrolase Proteins 0.000 claims description 22
108020004414 DNA Proteins 0.000 claims description 20
230000014509 gene expression Effects 0.000 claims description 16
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
150000007523 nucleic acids Chemical class 0.000 claims description 14
108020004707 nucleic acids Proteins 0.000 claims description 13
102000039446 nucleic acids Human genes 0.000 claims description 13
102000053602 DNA Human genes 0.000 claims description 10
239000002773 nucleotide Substances 0.000 claims description 10
125000003729 nucleotide group Chemical group 0.000 claims description 10
241000235058 Komagataella pastoris Species 0.000 claims description 9
210000005253 yeast cell Anatomy 0.000 claims description 6
241000235648 Pichia Species 0.000 claims description 5
210000001236 prokaryotic cell Anatomy 0.000 claims description 5
230000001105 regulatory effect Effects 0.000 claims description 5
239000003527 fibrinolytic agent Substances 0.000 claims description 3
210000003527 eukaryotic cell Anatomy 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
238000004113 cell culture Methods 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 abstract description 8
238000004519 manufacturing process Methods 0.000 abstract description 7
239000000463 material Substances 0.000 abstract description 7
239000003146 anticoagulant agent Substances 0.000 abstract description 2
230000002537 thrombolytic effect Effects 0.000 abstract description 2
230000009089 cytolysis Effects 0.000 abstract 1
238000011330 nucleic acid test Methods 0.000 description 65
150000001413 amino acids Chemical group 0.000 description 14
229920001223 polyethylene glycol Polymers 0.000 description 14
238000004090 dissolution Methods 0.000 description 13
229920000642 polymer Polymers 0.000 description 13
239000002202 Polyethylene glycol Substances 0.000 description 12
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 12
238000009739 binding Methods 0.000 description 11
239000002609 medium Substances 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000001963 growth medium Substances 0.000 description 9
125000000539 amino acid group Chemical group 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000000746 purification Methods 0.000 description 7
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000008103 glucose Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000011592 zinc chloride Substances 0.000 description 6
235000005074 zinc chloride Nutrition 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 5
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
125000003636 chemical group Chemical group 0.000 description 5
238000001212 derivatisation Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
235000015097 nutrients Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
241000894007 species Species 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
229960005356 urokinase Drugs 0.000 description 5
108091026890 Coding region Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000011149 active material Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
230000003480 fibrinolytic effect Effects 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
229930027917 kanamycin Natural products 0.000 description 4
229960000318 kanamycin Drugs 0.000 description 4
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
229930182823 kanamycin A Natural products 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
230000010076 replication Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
241000588722 Escherichia Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000011161 development Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002008 hemorrhagic effect Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
210000004897 n-terminal region Anatomy 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000007017 scission Effects 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
108010084455 Zeocin Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
239000010949 copper Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000006320 pegylation Effects 0.000 description 2
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
230000009465 prokaryotic expression Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000005932 reductive alkylation reaction Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000003998 snake venom Substances 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
241000271510 Agkistrodon contortrix Species 0.000 description 1
101000774685 Agkistrodon contortrix contortrix Snake venom metalloproteinase fibrolase Proteins 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
101000851165 Bothrops pirajai Snake venom metalloproteinase BpirMP Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010048964 Carotid artery occlusion Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108010019644 Oligodendrocyte Transcription Factor 2 Proteins 0.000 description 1
102100026058 Oligodendrocyte transcription factor 2 Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710118538 Protease Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
DTHZWUDUWBPDQI-UHFFFAOYSA-N [Zn].ClO Chemical compound [Zn].ClO DTHZWUDUWBPDQI-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000001254 nonsecretory effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
239000001120 potassium sulphate Substances 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
229920005653 propylene-ethylene copolymer Polymers 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Marine Sciences & Fisheries (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Hematology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BG106577A 1999-10-01 2002-04-04 Фибринолитично активен полипептид BG106577A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/411,329 US6261820B1 (en)	1999-10-01	1999-10-01	Fibronolytically active polypeptide
PCT/US2000/027029 WO2001025445A1 (en)	1999-10-01	2000-09-29	Fibrinolytically active polypeptide

Publications (1)

Publication Number	Publication Date
BG106577A true BG106577A (bg)	2003-04-30

Family

ID=23628486

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106577A BG106577A (bg)	1999-10-01	2002-04-04	Фибринолитично активен полипептид

Country Status (29)

Country	Link
US (4)	US6261820B1 (cs)
EP (2)	EP1605049A3 (cs)
JP (1)	JP2003511034A (cs)
KR (2)	KR100700753B1 (cs)
CN (2)	CN101230340A (cs)
AT (1)	ATE292180T1 (cs)
AU (1)	AU767827B2 (cs)
BG (1)	BG106577A (cs)
BR (1)	BR0014414A (cs)
CA (1)	CA2386185A1 (cs)
CZ (1)	CZ298502B6 (cs)
DE (1)	DE60019147T2 (cs)
DK (1)	DK1224298T3 (cs)
EA (2)	EA006487B1 (cs)
ES (1)	ES2240167T3 (cs)
HK (1)	HK1049351B (cs)
HU (1)	HUP0202650A3 (cs)
IL (1)	IL148787A0 (cs)
MX (1)	MXPA02003126A (cs)
NO (1)	NO20021501L (cs)
NZ (1)	NZ517951A (cs)
PL (1)	PL355017A1 (cs)
PT (1)	PT1224298E (cs)
RS (1)	RS20060033A (cs)
SG (1)	SG127720A1 (cs)
SK (1)	SK4232002A3 (cs)
WO (1)	WO2001025445A1 (cs)
YU (2)	YU59604A (cs)
ZA (1)	ZA200202206B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6440414B1 (en)	1999-10-01	2002-08-27	Amgen Inc.	Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en)	1999-10-01	2001-07-17	Amgen Inc.	Fibronolytically active polypeptide
US7033776B2 (en) *	1999-12-17	2006-04-25	Amgen Inc.	Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US6455269B1 (en) *	1999-12-17	2002-09-24	Amgen, Inc.	Method for localized administration of fibrinolytic metalloproteinases
US6523647B2 (en) *	2001-05-21	2003-02-25	Hydro Mobile Inc.	Elevating platform assembly
EP1482882B1 (en) *	2002-02-11	2011-09-14	Gold-T Tech, Inc.	Implantable device for preventing thrombus formation
US7016409B2 (en) *	2003-11-12	2006-03-21	Sony Corporation	Apparatus and method for use in providing dynamic bit rate encoding
ES2239532B1 (es) *	2004-02-06	2006-11-01	Proyecto De Biomedicina Cima S.L.	Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
US20070141625A1 (en) *	2005-02-03	2007-06-21	Santos Jose H	Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
EP1986568B1 (en)	2006-02-03	2017-04-05	Covidien LP	Methods and devices for restoring blood flow within blocked vasculature
WO2010102307A1 (en)	2009-03-06	2010-09-10	Lazarus Effect, Inc.	Retrieval systems and methods for use thereof
US10207240B2 (en)	2009-11-03	2019-02-19	Gen9, Inc.	Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
WO2012129363A2 (en)	2011-03-24	2012-09-27	President And Fellows Of Harvard College	Single cell nucleic acid detection and analysis
CN107873054B (zh)	2014-09-09	2022-07-12	博德研究所	用于复合单细胞核酸分析的基于微滴的方法和设备
US10456560B2 (en)	2015-02-11	2019-10-29	Covidien Lp	Expandable tip medical devices and methods
US11873483B2 (en)	2015-03-11	2024-01-16	The Broad Institute, Inc.	Proteomic analysis with nucleic acid identifiers
US11092607B2 (en)	2015-10-28	2021-08-17	The Board Institute, Inc.	Multiplex analysis of single cell constituents
WO2017075297A1 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	High-throughput dynamic reagent delivery system
US12071663B2 (en)	2016-01-15	2024-08-27	Massachusetts Institute Of Technology	Semi-permeable arrays for analyzing biological systems and methods of using same
US11072816B2 (en)	2017-05-03	2021-07-27	The Broad Institute, Inc.	Single-cell proteomic assay using aptamers
WO2022182799A1 (en) *	2021-02-23	2022-09-01	Clara Foods Co.	Compositions for preparing animal-free egg-like products

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2310133A2 (fr) *	1975-05-05	1976-12-03	Fabre Sa Pierre	Nouveau medicament comportant un activateur du plasminogene perfectionne
US4447236A (en) *	1982-02-05	1984-05-08	Cordis Corporation	Infusion catheter system
DE3330699A1 (de) *	1983-08-25	1985-03-07	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
US4610879A (en)	1984-01-06	1986-09-09	University Of Southern California	Fibrinolytic enzyme from snake vernom
CA1237482A (en) *	1984-03-09	1988-05-31	Frank B. Stiles	Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) *	1984-04-10	1988-07-05	Research Corporation	In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) *	1984-10-30	1989-12-05	Phillips Petroleum Company	Genes from pichia histidine pathway and uses thereof
US4855231A (en) *	1984-10-30	1989-08-08	Phillips Petroleum Company	Regulatory region for heterologous gene expression in yeast
US4837148A (en) *	1984-10-30	1989-06-06	Phillips Petroleum Company	Autonomous replication sequences for yeast strains of the genus pichia
US4818700A (en) *	1985-10-25	1989-04-04	Phillips Petroleum Company	Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) *	1986-02-18	1989-03-14	Phillips Petroleum Company	Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) *	1986-02-28	1991-03-19	Cardiovascular Imaging Systems, Inc.	Method for intravascular two-dimensional ultrasonography and recanalization
ZA889415B (en)	1987-12-18	1989-09-27	Chiron Corp	Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en)	1989-01-04	1990-07-12	Boston Scientific Corporation	Angioplasty catheter
US5222941A (en) *	1990-01-12	1993-06-29	Don Michael T Anthony	Method of dissolving an obstruction in a vessel
JPH05184352A (ja) *	1990-01-16	1993-07-27	Centro De Ing Genetica Y Biotecnol	ピヒアパストリス（Ｐｉｃｈｉａｐａｓｔｏｒｉｓ）酵母中での異種遺伝子の発現方法、発現ベクターおよび形質転換微生物
US5709676A (en) *	1990-02-14	1998-01-20	Alt; Eckhard	Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) *	1990-09-17	1993-10-05	E-Z-Em, Inc.	Pressure responsive valve catheter
US5167628A (en) *	1991-05-02	1992-12-01	Boyles Paul W	Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) *	1992-05-19	1995-01-10	Dubrul; Will R.	Vibrating catheter
EP0624642B1 (en)	1993-05-12	1999-01-20	Indian Council For Medical Research	Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) *	1993-07-22	1994-12-06	Micro Therapeutics, Inc.	Thrombectomy method and apparatus
EP0689843B1 (en)	1993-12-17	2003-09-10	Mochida Pharmaceutical Co., Ltd.	Composition containing soluble thrombomodulins
US5626564A (en) *	1995-03-31	1997-05-06	Creighton University	Adjustable sideholes catheter
US5830468A (en) *	1995-05-17	1998-11-03	The New York Blood Center, Inc.	Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) *	1995-05-17	2000-02-01	New York Blood, Inc.	Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) *	1996-05-10	1998-04-21	Xoma Corporation	Antithrombotic materials and methods
DE69734060T2 (de) *	1996-05-24	2006-06-29	Angiotech Pharmaceuticals, Inc., Vancouver	Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5951981A (en) *	1996-12-02	1999-09-14	Diatide, Inc.	Thrombolytic agents with antithrombotic activity
US6413760B1 (en) *	1997-04-15	2002-07-02	Genetics Institute, Inc.	Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
WO1999029838A1 (en) *	1997-12-09	1999-06-17	Bristol-Myers Squibb Company	Fibrinogen-converting enzyme hybrids
US6261820B1 (en)	1999-10-01	2001-07-17	Amgen Inc.	Fibronolytically active polypeptide
US6440414B1 (en)	1999-10-01	2002-08-27	Amgen Inc.	Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) *	1999-12-17	2002-09-24	Amgen, Inc.	Method for localized administration of fibrinolytic metalloproteinases
WO2002012283A2 (en)	2000-08-03	2002-02-14	Zymogenetics, Inc.	Disintegrin homologs, zsnk10, zsnk11, and zsnk12

1999
- 1999-10-01 US US09/411,329 patent/US6261820B1/en not_active Expired - Fee Related
2000
- 2000-09-20 YU YU59604A patent/YU59604A/sh unknown
- 2000-09-20 YU YU22502A patent/YU22502A/sh unknown
- 2000-09-29 WO PCT/US2000/027029 patent/WO2001025445A1/en not_active Ceased
- 2000-09-29 MX MXPA02003126A patent/MXPA02003126A/es active IP Right Grant
- 2000-09-29 NZ NZ517951A patent/NZ517951A/en unknown
- 2000-09-29 HU HU0202650A patent/HUP0202650A3/hu unknown
- 2000-09-29 PT PT00965554T patent/PT1224298E/pt unknown
- 2000-09-29 IL IL14878700A patent/IL148787A0/xx unknown
- 2000-09-29 CN CNA2008100053253A patent/CN101230340A/zh active Pending
- 2000-09-29 JP JP2001528597A patent/JP2003511034A/ja not_active Withdrawn
- 2000-09-29 KR KR1020067019636A patent/KR100700753B1/ko not_active Expired - Fee Related
- 2000-09-29 RS YUP-2006/0033A patent/RS20060033A/sr unknown
- 2000-09-29 DK DK00965554T patent/DK1224298T3/da active
- 2000-09-29 DE DE60019147T patent/DE60019147T2/de not_active Expired - Fee Related
- 2000-09-29 EA EA200400290A patent/EA006487B1/ru unknown
- 2000-09-29 PL PL00355017A patent/PL355017A1/xx not_active IP Right Cessation
- 2000-09-29 EP EP05006771A patent/EP1605049A3/en not_active Withdrawn
- 2000-09-29 SG SG200401889A patent/SG127720A1/en unknown
- 2000-09-29 KR KR1020027004225A patent/KR100711312B1/ko not_active Expired - Fee Related
- 2000-09-29 SK SK423-2002A patent/SK4232002A3/sk not_active Application Discontinuation
- 2000-09-29 EA EA200200410A patent/EA005944B1/ru not_active IP Right Cessation
- 2000-09-29 AU AU76254/00A patent/AU767827B2/en not_active Ceased
- 2000-09-29 EP EP00965554A patent/EP1224298B1/en not_active Expired - Lifetime
- 2000-09-29 ES ES00965554T patent/ES2240167T3/es not_active Expired - Lifetime
- 2000-09-29 HK HK03100667.9A patent/HK1049351B/en not_active IP Right Cessation
- 2000-09-29 CZ CZ20021034A patent/CZ298502B6/cs not_active IP Right Cessation
- 2000-09-29 AT AT00965554T patent/ATE292180T1/de not_active IP Right Cessation
- 2000-09-29 CA CA002386185A patent/CA2386185A1/en not_active Abandoned
- 2000-09-29 CN CNB008163219A patent/CN100357430C/zh not_active Expired - Fee Related
- 2000-09-29 BR BR0014414-2A patent/BR0014414A/pt not_active Application Discontinuation
2001
- 2001-05-01 US US09/846,729 patent/US6617145B2/en not_active Expired - Fee Related
2002
- 2002-03-19 ZA ZA200202206A patent/ZA200202206B/en unknown
- 2002-03-26 NO NO20021501A patent/NO20021501L/no not_active Application Discontinuation
- 2002-04-04 BG BG106577A patent/BG106577A/bg unknown
2003
- 2003-05-20 US US10/441,667 patent/US7195903B2/en not_active Expired - Fee Related
2007
- 2007-02-06 US US11/702,972 patent/US20080058256A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR0014414A (pt)	2002-06-11
US20080058256A1 (en)	2008-03-06
KR100711312B1 (ko)	2007-04-27
DK1224298T3 (da)	2005-05-30
US7195903B2 (en)	2007-03-27
KR20020047208A (ko)	2002-06-21
AU767827B2 (en)	2003-11-27
NZ517951A (en)	2004-02-27
EA006487B1 (ru)	2005-12-29
US6261820B1 (en)	2001-07-17
DE60019147T2 (de)	2006-05-11
CZ20021034A3 (cs)	2003-06-18
ATE292180T1 (de)	2005-04-15
CZ298502B6 (cs)	2007-10-24
EP1224298A1 (en)	2002-07-24
MXPA02003126A (es)	2002-09-30
SK4232002A3 (en)	2003-09-11
CN100357430C (zh)	2007-12-26
IL148787A0 (en)	2002-09-12
SG127720A1 (en)	2006-12-29
RS20060033A (sr)	2006-12-15
EP1224298B1 (en)	2005-03-30
EA005944B1 (ru)	2005-08-25
YU22502A (sh)	2005-07-19
NO20021501D0 (no)	2002-03-26
KR20060114034A (ko)	2006-11-03
HK1049351B (en)	2005-07-29
PT1224298E (pt)	2005-06-30
EA200200410A1 (ru)	2002-10-31
NO20021501L (no)	2002-05-31
DE60019147D1 (en)	2005-05-04
JP2003511034A (ja)	2003-03-25
HUP0202650A3 (en)	2005-01-28
EP1605049A3 (en)	2006-12-13
EA200400290A1 (ru)	2005-02-24
WO2001025445A1 (en)	2001-04-12
KR100700753B1 (ko)	2007-03-28
CN101230340A (zh)	2008-07-30
CA2386185A1 (en)	2001-04-12
AU7625400A (en)	2001-05-10
HK1049351A1 (en)	2003-05-09
CN1402788A (zh)	2003-03-12
US6617145B2 (en)	2003-09-09
ZA200202206B (en)	2002-12-24
YU59604A (sh)	2005-11-28
ES2240167T3 (es)	2005-10-16
US20020058322A1 (en)	2002-05-16
EP1605049A2 (en)	2005-12-14
US20030186422A1 (en)	2003-10-02
HUP0202650A2 (hu)	2002-12-28
PL355017A1 (en)	2004-03-22

Publication	Publication Date	Title
US20080058256A1 (en)	2008-03-06	Methods for the treatment of thrombosis
JP4722989B2 (ja)	2011-07-13	新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
JP2002502235A (ja)	2002-01-22	新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
CN104711243B (zh)	2019-06-11	重组的弹性蛋白酶蛋白质及其制备方法和用途
WO2015100768A1 (zh)	2015-07-09	聚乙二醇化的组织激肽释放酶及其制备方法和应用
JP3469247B2 (ja)	2003-11-25	組換えリボヌクレアーゼタンパク質
JP2002510209A (ja)	2002-04-02	インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
RU2426745C2 (ru)	2011-08-20	Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция
JP2025505131A (ja)	2025-02-21	ＩｇＡプロテアーゼトランケート、ＩｇＡプロテアーゼトランケートを含む融合タンパク質及びその用途
AU2004200776B2 (en)	2006-07-13	Fibrinolytically active polypeptide
HK1079242A (en)	2006-03-31	Fibrinolytically active polypeptide
NZ530114A (en)	2006-02-24	Fibrinolytically active polypeptide